Today marks an important milestone for HotSpot Therapeutics as we announce our Series B financing, but it also marks a milestone for me personally – 20 years in the business of biotech.
This blog was written by Jonathan Montagu, CEO and co-founder of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC.
Read more .
When the pandemic struck, biotechnology chief executives suddenly faced questions about how to keep their workers safe, their research moving and their budgets intact.
I stood in front of 15 skeptical parents and prepared to sell them on an improbable mission.
They had all signed their daughters up for the first-grade basketball team. I would be coaching that team. And I was here to advise them that this would not be the type of experience their six- and seven-year-olds were used to.
This blog was written by Josh Brumm, CEO of Dyne Therapeutics, as part of the From The Trenches feature of LifeSciVC.
What a difference a little time makes.
When Bruce originally encouraged me to be a contributor to From The Trenches, life was “the way it used to be.” And as Atlas’ Head of Talent, I mused about writing on topics related to Executive Search, Leadership, and Venture in general. But in what feels like a blink of an eye, the world feels (and is) incredibly different. With the COVID-19 pandemic impacting our lives and consciousness, now may not be time to discuss topics that seem far from important.
This blog was written by Andrea DiMella, VP and Head of Talent at Atlas Venture, as part of the From The Trenches feature of LifeSciVC.
Two years ago, Accent Therapeutics got off a $40 million series A to target RNA-modifying proteins in cancer; now, in the middle of a pandemic, it’s still managed to bring in a respectable $63 million second funding round.